ADAR1 Capital Management, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), ADAR1 Capital Management, LLC reported 260 stock positions worth $2.1 billion. Its top holding was Abivax SA-ADR (ABVX) at 11.4% of the portfolio, followed by Protagonist Therapeutics (PTGX, 5.6%) and Roivant Sciences (ROIV, 5.3%). Compared with Q1 2026, it opened 40 new positions, sold out of 70, added to 98 and reduced 64. The biggest buy was Abivax SA-ADR (ABVX, shares +29%) and the biggest sale an exit from Terns Pharmaceuticals (TERN).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001940272
- Portfolio Value
- $2.1B (Q2 2026)
- SEC Filing
- 0001940272-26-000015 ↗ filed Aug 14, 2026
Holdings Value
Holdings 260 stocks · $2.1B
| ABVX Abivax SA-ADR | 11.39% | 1,804,703 | $240.5M | Add +29.5% |
| PTGX Protagonist Therapeutics Inc. | 5.58% | 960,863 | $117.8M | Reduce -3.4% |
| ROIV Roivant Sciences Ltd. | 5.29% | 3,157,008 | $111.7M | Reduce -3.9% |
| SPY SS SPDR S&P 500 ETF Trust-US | 4.56% | 129,087 | $96.4M | Add +70.0% |
| IMVT Immunovant Inc. | 4.25% | 2,330,716 | $89.8M | Reduce -13.0% |
| ZLAB Zai Lab Ltd.-ADR | 3.03% | 3,369,034 | $64.0M | Add +136.4% |
| AGIO Agios Pharmaceuticals Inc. | 2.26% | 1,288,053 | $47.8M | Add +815.6% |
| CRNX Crinetics Pharmaceuticals Inc. | 2.17% | 1,222,080 | $45.7M | Add +7.3% |
| BOXX Alpha Architect 1-3 MNTH Box | 1.87% | 337,125 | $39.5M | No change |
| CYTK Cytokinetics Inc. | 1.85% | 457,907 | $39.0M | Reduce -27.6% |
| SEPN Septerna Inc. | 1.49% | 940,747 | $31.5M | Reduce -13.7% |
| AVR Anteris Technologies Global | 1.47% | 3,145,096 | $31.0M | Reduce -17.0% |
| EDIT Editas Medicine Inc. | 1.36% | 8,889,000 | $28.8M | New |
| DNLI Denali Therapeutics Inc. | 1.25% | 1,029,080 | $26.5M | Reduce -45.0% |
| SYRE Spyre Therapeutics Inc. | 1.19% | 283,982 | $25.2M | Reduce -16.1% |
| VIR Vir Biotechnology Inc. | 1.19% | 2,456,677 | $25.0M | Reduce -10.5% |
| PRAX Praxis Precision Medicines I | 1.18% | 74,253 | $24.9M | Add +4850.2% |
| INSM Insmed Inc. | 1.15% | 228,520 | $24.4M | Add +545.7% |
| CLDX Celldex Therapeutics Inc. | 1.09% | 619,542 | $23.1M | Add +44.8% |
| VKTX Viking Therapeutics Inc. | 1.06% | 574,038 | $22.4M | Add +152.1% |
| TSHA Taysha Gene Therapies Inc. | 0.98% | 3,040,466 | $20.7M | Add +2.0% |
| MNPR Monopar Therapeutics Inc. | 0.95% | 217,595 | $20.1M | Reduce -17.7% |
| OVID Ovid Therapeutics Inc. | 0.94% | 7,417,479 | $20.0M | Add +63.2% |
| ELVN Enliven Therapeutics Inc. | 0.93% | 387,718 | $19.7M | Add +17.6% |
| ENTA Enanta Pharmaceuticals Inc. | 0.93% | 1,344,510 | $19.6M | Add +2518.0% |
| NKTR Nektar Therapeutics | 0.81% | 244,184 | $17.0M | Add +51.4% |
| INSP Inspire Medical Systems Inc. | 0.79% | 374,617 | $16.7M | Reduce -7.5% |
| RVMD Revolution Medicines Inc. | 0.78% | 87,509 | $16.4M | Reduce -34.6% |
| ESTA Establishment Labs Holdings | 0.75% | 185,619 | $15.9M | Reduce -13.1% |
| PRTA Prothena Corp. PLC | 0.72% | 1,554,535 | $15.2M | Reduce -1.7% |
| RYTM Rhythm Pharmaceuticals Inc. | 0.72% | 136,158 | $15.1M | Reduce -35.6% |
| IKT Inhibikase Therapeutics Inc. | 0.71% | 7,387,205 | $15.0M | Add +11.8% |
| QURE Uniqure NV | 0.71% | 324,672 | $15.0M | Add +326.1% |
| RLYB Rallybio Corp. | 0.70% | 926,352 | $14.8M | Add +4411.1% |
| REGN Regeneron Pharmaceuticals | 0.66% | 22,208 | $13.8M | Add +82.7% |
| IVA Inventiva SA - ADR | 0.65% | 3,606,656 | $13.6M | Add +65.9% |
| STRO Sutro Biopharma Inc. | 0.64% | 404,014 | $13.4M | Reduce -23.0% |
| IONS Ionis Pharmaceuticals Inc. | 0.62% | 166,286 | $13.2M | Add +3.7% |
| BBIO Bridgebio Pharma Inc. | 0.62% | 176,689 | $13.2M | Add +87.4% |
| SRPT Sarepta Therapeutics Inc. | 0.62% | 730,649 | $13.1M | Add +178.8% |
| CTMX Cytomx Therapeutics Inc. | 0.60% | 3,365,118 | $12.6M | Reduce -1.3% |
| VOR Vor Biopharma Inc. | 0.59% | 680,626 | $12.5M | New |
| BIL SS SPDR BB 1-3M T-Bill ETF | 0.59% | 135,585 | $12.4M | No change |
| EQ Equillium Inc. | 0.57% | 3,758,569 | $12.0M | Add +0.9% |
| ANL Adlai Nortye Group Ltd. | 0.55% | 1,017,805 | $11.7M | Add +763.2% |
| CLYM Climb Bio Inc. | 0.51% | 822,649 | $10.7M | Add +37.6% |
| HLXC Helix Acquisition Corp. Class A | 0.50% | 1,000,000 | $10.6M | No change |
| ZURA Zura Bio Ltd. | 0.49% | 1,759,295 | $10.4M | Add +179.1% |
| OKUR Onkure Therapeutics Inc. Class A | 0.48% | 2,238,684 | $10.2M | Reduce -8.1% |
| MAZE Maze Therapeutics Inc. | 0.48% | 339,276 | $10.1M | Add +577.3% |
| XENE Xenon Pharmaceuticals Inc. | 0.48% | 166,550 | $10.1M | Reduce -27.2% |
| TEVA Teva Pharmaceutical-SP ADR | 0.45% | 277,848 | $9.4M | Add +3.5% |
| URGN Urogen Pharma Ltd. | 0.44% | 252,395 | $9.3M | Reduce -36.2% |
| FTH Faeth Therapeutics Inc. | 0.43% | 361,010 | $9.0M | New |
| AMLX Amylyx Pharmaceuticals Inc. | 0.42% | 494,378 | $8.9M | Reduce -50.6% |
| DBVT DBV Technologies SA-Spon ADR | 0.41% | 528,295 | $8.7M | Reduce -47.8% |
| SVRA Savara Inc. | 0.41% | 1,403,409 | $8.6M | Reduce -4.2% |
| PCVX Vaxcyte Inc. | 0.40% | 146,034 | $8.5M | Reduce -43.6% |
| CGON CG Oncology Inc. | 0.40% | 118,664 | $8.4M | Reduce -36.1% |
| MLYS Mineralys Therapeutics Inc. | 0.38% | 298,886 | $8.1M | Add +93.2% |
| ASND Ascendis Pharma A/S | 0.36% | 28,604 | $7.6M | Add +14.3% |
| AMAN Amanat Acquisition Corp. Class A | 0.36% | 750,000 | $7.6M | New |
| NRIX Nurix Therapeutics Inc. | 0.36% | 313,236 | $7.6M | Add +458.6% |
| BHVN Biohaven Ltd. | 0.35% | 501,687 | $7.5M | Add +1020.4% |
| PRME Prime Medicine Inc. | 0.35% | 1,997,552 | $7.4M | Add +1.2% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.35% | 674,695 | $7.3M | Add +35.0% |
| IRD Opus Genetics Inc. | 0.35% | 1,783,781 | $7.3M | Reduce -3.5% |
| LXEO Lexeo Therapeutics Inc. | 0.35% | 1,565,950 | $7.3M | Add +6.7% |
| DMRA Damora Therapeutics Inc. | 0.34% | 280,000 | $7.3M | Add +0.4% |
| REPL Replimune Group Inc. | 0.34% | 655,784 | $7.3M | Reduce -58.6% |
| LONA Leonabio Inc. | 0.34% | 777,100 | $7.1M | Add +6.8% |
| KRRO Korro Bio Inc. | 0.34% | 540,054 | $7.1M | No change |
| RACC Research Alliance Corp. Class A | 0.33% | 650,000 | $7.0M | New |
| IFRX Inflarx NV | 0.32% | 3,000,000 | $6.7M | Add +1795.5% |
| RLAY Relay Therapeutics Inc. | 0.32% | 358,333 | $6.7M | New |
| JANX Janux Therapeutics Inc. | 0.31% | 420,881 | $6.5M | Add +41.0% |
| PLRX Pliant Therapeutics Inc. | 0.30% | 5,509,724 | $6.3M | Add +113.1% |
| WHWK Whitehawk Therapeutics Inc. | 0.29% | 1,341,394 | $6.1M | Add +943.9% |
| KRYS Krystal Biotech Inc. | 0.29% | 16,420 | $6.1M | Reduce -18.0% |
| ABUS Arbutus Biopharma Corp. | 0.29% | 1,268,147 | $6.1M | Reduce -59.5% |
| PFE Pfizer Inc. | 0.29% | 252,400 | $6.1M | Add +226.1% |
| BHF Brighthouse Financial Inc. | 0.29% | 95,523 | $6.0M | No change |
| EWTX Edgewise Therapeutics Inc. | 0.28% | 143,199 | $5.8M | Add +58.1% |
| ALEC Alector Inc. | 0.27% | 2,883,583 | $5.8M | Add +174.6% |
| FULC Fulcrum Therapeutics Inc. | 0.27% | 1,565,029 | $5.7M | Add +1098.7% |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.27% | 69,800 | $5.7M | Reduce -0.7% |
| ABOS Acumen Pharmaceuticals Inc. | 0.27% | 2,111,334 | $5.6M | Reduce -2.1% |
| OACCU Oaktree Acquisition III Life | 0.27% | 516,482 | $5.6M | No change |
| GMED Globus Medical Inc. Class A | 0.26% | 70,100 | $5.5M | Add +248.8% |
| GLUE Monte Rosa Therapeutics Inc. | 0.25% | 216,752 | $5.2M | Add +0.5% |
| DGAC.U Disciplined Growth Acquisiti | 0.24% | 500,000 | $5.0M | New |
| BHAVU Bhav Acquisition Corp. | 0.24% | 495,000 | $5.0M | No change |
| DHR Danaher Corp. | 0.23% | 25,932 | $4.9M | Reduce -16.2% |
| BOLD Boundless Bio Inc. | 0.23% | 1,968,216 | $4.9M | New |
| AVLN Avalyn Pharma Inc. | 0.23% | 146,447 | $4.8M | New |
| SPRY Ars Pharmaceuticals Inc. | 0.23% | 600,999 | $4.8M | Reduce -55.9% |
| ATAI Ataibeckley Inc. | 0.23% | 913,242 | $4.8M | No change |
| PRLD Prelude Therapeutics Inc. | 0.23% | 900,900 | $4.8M | Add +489.5% |
| JATT Jatt II Acquisition Corp. | 0.22% | 417,724 | $4.7M | New |
| RNTX Rein Therapeutics Inc. | 0.22% | 4,500,000 | $4.7M | New |
Options reported separately and not counted above: IWM puts ($18.8M), SPY puts ($18.7M), XBI puts ($10.7M), ABVX calls ($5.9M), KVACF calls ($930K), AMLX puts ($720K), RARE calls ($668K), NVO calls ($623K), CRBP calls ($563K), STI calls ($125K).
Other holdings (7): bonds, preferreds, convertibles and warrants · $5.8M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 20,000 | $3.5M | No change |
| ARROWHEAD RESEARCH CORP (ARWR 0 01/15/32) | NOTE 1/1 · principal | 10,000 | $1.2M | New |
| TRAVERE THERAPEUTICS INC (TVTX 0.5 05/15/32) | NOTE 0.500% 5/1 · principal | 10,000 | $1.0M | New |
| BRIDGEBIO PHARMA INC (BBIO 1.75 03/01/31) | NOTE 1.750% 3/0 · principal | 30,000 | $50K | No change |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | 45,000 | $49K | No change |
| ASPCR A Spac III Acquisition Corp. | RIGHT 01/02/2026 | 215,000 | $19K | No change |
| BSAAR Best Spac I Acquisition - RT | RIGHT 05/27/2030 | 100,000 | $17K | New |
Total filed on the 13F, all lines: $2.1B.
Portfolio Sells Q1 2026 → Q2 2026
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −2.92 |
| BEAM Beam Therapeutics Inc. | Sold out | 0.00% | −2.09 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −1.21 |
| DNLI Denali Therapeutics Inc. | Reduce -45.0% | 1.25% | −0.93 |
| DBVT DBV Technologies SA-Spon ADR | Reduce -47.8% | 0.41% | −0.87 |
| SNY Sanofi-ADR | Reduce -82.0% | 0.12% | −0.81 |
| PTGX Protagonist Therapeutics Inc. | Reduce -3.4% | 5.58% | −0.78 |
| CYTK Cytokinetics Inc. | Reduce -27.6% | 1.85% | −0.68 |
| ABUS Arbutus Biopharma Corp. | Reduce -59.5% | 0.29% | −0.57 |
| PCVX Vaxcyte Inc. | Reduce -43.6% | 0.40% | −0.51 |
| MLTX Moonlake Immunotherapeutics | Reduce -94.1% | 0.02% | −0.49 |
| INSP Inspire Medical Systems Inc. | Reduce -7.5% | 0.79% | −0.48 |
| SPRY Ars Pharmaceuticals Inc. | Reduce -55.9% | 0.23% | −0.43 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -50.6% | 0.42% | −0.42 |
| MPLT Maplight Therapeutics Inc. | Reduce -92.9% | 0.04% | −0.42 |
| VRTX Vertex Pharmaceuticals Inc. | Sold out | 0.00% | −0.41 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -35.6% | 0.72% | −0.40 |
| REPL Replimune Group Inc. | Reduce -58.6% | 0.34% | −0.39 |
| CTMX Cytomx Therapeutics Inc. | Reduce -1.3% | 0.60% | −0.37 |
| CGON CG Oncology Inc. | Reduce -36.1% | 0.40% | −0.36 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −0.36 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -27.2% | 0.48% | −0.33 |
| VIR Vir Biotechnology Inc. | Reduce -10.5% | 1.19% | −0.31 |
| LLY Eli Lilly & Co. | Sold out | 0.00% | −0.28 |
| DNTH Dianthus Therapeutics Inc. | Sold out | 0.00% | −0.28 |
| BLTE Belite Bio Inc. - ADR | Sold out | 0.00% | −0.26 |
| ROIV Roivant Sciences Ltd. | Reduce -3.9% | 5.29% | −0.23 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −0.22 |
| PRTA Prothena Corp. PLC | Reduce -1.7% | 0.72% | −0.21 |
| AVBP Arrivent Biopharma Inc. | Sold out | 0.00% | −0.20 |
| EVMN Evommune Inc. | Reduce -43.5% | 0.07% | −0.19 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −0.18 |
| IRD Opus Genetics Inc. | Reduce -3.5% | 0.35% | −0.16 |
| MASI Masimo Corp. | Sold out | 0.00% | −0.16 |
| STRO Sutro Biopharma Inc. | Reduce -23.0% | 0.64% | −0.16 |
| TFX Teleflex Inc. | Sold out | 0.00% | −0.15 |
| IVVD Invivyd Inc. | Reduce -0.4% | 0.16% | −0.14 |
| BIOA Bioage Labs Inc. | Sold out | 0.00% | −0.14 |
| OKUR Onkure Therapeutics Inc. Class A | Reduce -8.1% | 0.48% | −0.13 |
| DHR Danaher Corp. | Reduce -16.2% | 0.23% | −0.12 |
| AEXA American Exceptionalism Class A | Reduce -42.5% | 0.12% | −0.12 |
| ALKS Alkermes PLC | Sold out | 0.00% | −0.10 |
| SEPN Septerna Inc. | Reduce -13.7% | 1.49% | −0.10 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −0.10 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −0.09 |
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −0.09 |
| UNH Unitedhealth Group Inc. | Sold out | 0.00% | −0.09 |
| SXT Sensient Technologies Corp. | Sold out | 0.00% | −0.08 |
| SVRA Savara Inc. | Reduce -4.2% | 0.41% | −0.08 |
| SDGR Schrodinger Inc. | Sold out | 0.00% | −0.07 |
Portfolio Buys Q1 2026 → Q2 2026
| ABVX Abivax SA-ADR | Add +29.5% | 11.39% | +1.98 |
| AGIO Agios Pharmaceuticals Inc. | Add +815.6% | 2.26% | +1.97 |
| SPY SS SPDR S&P 500 ETF Trust-US | Add +70.0% | 4.56% | +1.57 |
| ZLAB Zai Lab Ltd.-ADR | Add +136.4% | 3.03% | +1.41 |
| EDIT Editas Medicine Inc. | New | 1.36% | +1.36 |
| PRAX Praxis Precision Medicines I | Add +4850.2% | 1.18% | +1.15 |
| ENTA Enanta Pharmaceuticals Inc. | Add +2518.0% | 0.93% | +0.89 |
| INSM Insmed Inc. | Add +545.7% | 1.15% | +0.80 |
| RLYB Rallybio Corp. | Add +4411.1% | 0.70% | +0.69 |
| QURE Uniqure NV | Add +326.1% | 0.71% | +0.63 |
| VKTX Viking Therapeutics Inc. | Add +152.1% | 1.06% | +0.61 |
| VOR Vor Biopharma Inc. | New | 0.59% | +0.59 |
| ANL Adlai Nortye Group Ltd. | Add +763.2% | 0.55% | +0.50 |
| FTH Faeth Therapeutics Inc. | New | 0.43% | +0.43 |
| MAZE Maze Therapeutics Inc. | Add +577.3% | 0.48% | +0.39 |
| AMAN Amanat Acquisition Corp. Class A | New | 0.36% | +0.36 |
| OVID Ovid Therapeutics Inc. | Add +63.2% | 0.94% | +0.33 |
| BHVN Biohaven Ltd. | Add +1020.4% | 0.35% | +0.33 |
| RACC Research Alliance Corp. Class A | New | 0.33% | +0.33 |
| RLAY Relay Therapeutics Inc. | New | 0.32% | +0.32 |
| IFRX Inflarx NV | Add +1795.5% | 0.32% | +0.31 |
| NRIX Nurix Therapeutics Inc. | Add +458.6% | 0.36% | +0.31 |
| SRPT Sarepta Therapeutics Inc. | Add +178.8% | 0.62% | +0.28 |
| CLDX Celldex Therapeutics Inc. | Add +44.8% | 1.09% | +0.27 |
| ZURA Zura Bio Ltd. | Add +179.1% | 0.49% | +0.26 |
| WHWK Whitehawk Therapeutics Inc. | Add +943.9% | 0.29% | +0.26 |
| CLYM Climb Bio Inc. | Add +37.6% | 0.51% | +0.26 |
| DGAC.U Disciplined Growth Acquisiti | New | 0.24% | +0.24 |
| BOLD Boundless Bio Inc. | New | 0.23% | +0.23 |
| AVLN Avalyn Pharma Inc. | New | 0.23% | +0.23 |
| JATT Jatt II Acquisition Corp. | New | 0.22% | +0.22 |
| RNTX Rein Therapeutics Inc. | New | 0.22% | +0.22 |
| FULC Fulcrum Therapeutics Inc. | Add +1098.7% | 0.27% | +0.21 |
| BBIO Bridgebio Pharma Inc. | Add +87.4% | 0.62% | +0.20 |
| PRLD Prelude Therapeutics Inc. | Add +489.5% | 0.23% | +0.20 |
| APGE Apogee Therapeutics Inc. | New | 0.19% | +0.19 |
| TSHA Taysha Gene Therapies Inc. | Add +2.0% | 0.98% | +0.17 |
| SGMT Sagimet Biosciences Inc. Class A | New | 0.16% | +0.16 |
| GMED Globus Medical Inc. Class A | Add +248.8% | 0.26% | +0.16 |
| PFE Pfizer Inc. | Add +226.1% | 0.29% | +0.16 |
| ELVN Enliven Therapeutics Inc. | Add +17.6% | 0.93% | +0.15 |
| ALEC Alector Inc. | Add +174.6% | 0.27% | +0.14 |
| ZNTL Zentalis Pharmaceuticals Inc. | Add +351.3% | 0.15% | +0.13 |
| MLYS Mineralys Therapeutics Inc. | Add +93.2% | 0.38% | +0.13 |
| SLN Silence Therapeutics PLC-ADR | Add +96.5% | 0.18% | +0.12 |
| EQ Equillium Inc. | Add +0.9% | 0.57% | +0.12 |
| ENGN Engene Therapeutics Inc. | Add +1474.6% | 0.17% | +0.12 |
| XNCR Xencor Inc. | Add +148.3% | 0.18% | +0.11 |
| NKTR Nektar Therapeutics | Add +51.4% | 0.81% | +0.10 |
| EWTX Edgewise Therapeutics Inc. | Add +58.1% | 0.28% | +0.10 |
Options Activity Q1 2026 → Q2 2026
| IWM iShares Russell 2000 ETF | put | Add +127.3% | 62,500 | $18.8M |
| SPY SS SPDR S&P 500 ETF Trust-US | put | New | 25,000 | $18.7M |
| XBI SS SPDR S&P Biotech ETF | put | Add +349.3% | 67,400 | $10.7M |
| TERN Terns Pharmaceuticals Inc. | call | Sold out | 200,000 | $10.5Mbefore exit |
| ABVX Abivax SA-ADR | call | Add +0.9% | 44,400 | $5.9M |
| LQDA Liquidia Corp. | put | Sold out | 100,000 | $3.8Mbefore exit |
| QURE Uniqure NV | call | Sold out | 100,000 | $1.6Mbefore exit |
| KPTI Karyopharm Therapeutics Inc. | call | Sold out | 205,200 | $1.1Mbefore exit |
| REPL Replimune Group Inc. | call | Sold out | 100,000 | $765Kbefore exit |
| AMLX Amylyx Pharmaceuticals Inc. | put | New | 40,100 | $720K |
| GUTS Fractyl Health Inc. | call | Sold out | 1,428,571 | $654Kbefore exit |
| CRBP Corbus Pharmaceuticals Holdi | call | Add +71.4% | 60,000 | $563K |
| MLTX Moonlake Immunotherapeutics | call | Sold out | 20,000 | $373Kbefore exit |
| QUINCE THERAPEUTICS INC | put | Sold out | 50,000 | $5Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q1 2026 → Q2 2026
| ARROWHEAD RESEARCH CORP (ARWR 0 01/15/32) | NOTE 1/1 · principal | New | 10,000 | $1.2M |
| TRAVERE THERAPEUTICS INC (TVTX 0.5 05/15/32) | NOTE 0.500% 5/1 · principal | New | 10,000 | $1.0M |
| BSAAR Best Spac I Acquisition - RT | RIGHT 05/27/2030 | New | 100,000 | $17K |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 260 | $2.1B | ABVX, PTGX, ROIV, SPY, IMVT |
| Q1 2026 | 290 | $1.6B | ABVX, PTGX, ROIV, IMVT, SPY |
| Q4 2025Amended | 248 | $1.3B | ABVX, PTGX, ROIV, IMVT, RNAM |
| Q3 2025 | 196 | $1.0B | ABVX, KROS, PTGX, ROIV, BOXX |
| Q2 2025 | 192 | $609.1M | KROS, PTGX, BOXX, ZLAB, ABVX |
| Q1 2025 | 185 | $505.1M | PTGX, BOXX, ROIV, ZLAB, IMVT |
| Q4 2024 | 185 | $469.3M | ROIV, PTGX, BOXX, ZLAB, IMVT |
| Q3 2024 | 244 | $596.5M | CYTK, PTGX, BBIO, BOXX, ROIV |
| Q2 2024 | 231 | $496.6M | PTGX, CYTK, ROIV, BOXX, BBIO |
| Q1 2024 | 223 | $366.2M | BOXX, ROIV, ALNY, PTGX, CYTK |